Stock 2142 HBM HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

HBM Holdings Limited Stock

Equities

2142

KYG4403H1002

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 23:36:01 2024-04-28 EDT 		5-day change 1st Jan Change
1.29 HKD +3.20% Intraday chart for HBM Holdings Limited +19.44% -33.51%
04-02 HBM Holdings Returns to Profitability in 2023 MT
03-28 HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2021 4.31M 33.72M 5.88M Sales 2022 40.66M 318M 55.49M Capitalization 267M 2.09B 365M
Net income 2021 -138M -1.08B -188M Net income 2022 -137M -1.07B -187M EV / Sales 2021 123 x
Net cash position 2021 198M 1.55B 270M Net cash position 2022 81.58M 639M 111M EV / Sales 2022 4.57 x
P/E ratio 2021
-5.28 x
P/E ratio 2022
-1.91 x
Employees 177
Yield 2021 *
-
Yield 2022
-
Free-Float 79.47%
More Fundamentals * Assessed data

Chart HBM Holdings Limited

Dynamic Chart

Latest news about HBM Holdings Limited

HBM Holdings Returns to Profitability in 2023 MT
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal MT
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication MT
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S CI
HBM to Swing to 2023 Profit MT
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023 CI
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023. CI
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5% MT
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab CI
HBM Holdings Limited Announces Executive Changes CI
HBM Swings to Profit in H1; Shares Up 6% MT
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US MT
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors CI
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news

Press releases HBM Holdings Limited

Harbour BioMed Reports Full Year 2023 Financial Results PR
Harbour BioMed Announces Positive Profit Alert PR
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate AQ
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director PR
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation PR
More press releases

News in other languages on HBM Holdings Limited

HBM verkauft Entwicklungsrechte an Astrazeneca
More news

Quotes and Performance

1 day+3.20%
1 week+19.44%
Current month-6.52%
1 month-5.15%
3 months-23.67%
6 months-11.03%
Current year-33.51%
More quotes

Highs and lows

1 week
1.05
Extreme 1.05
1.35
1 month
1.01
Extreme 1.01
1.47
Current year
1.01
Extreme 1.01
1.95
1 year
1.01
Extreme 1.01
2.03
3 years
0.87
Extreme 0.87
12.40
5 years
0.87
Extreme 0.87
12.40
10 years
0.87
Extreme 0.87
12.40
More quotes

Managers and Directors - HBM Holdings Limited

Managers TitleAgeSince
Jing Song Wang CEO
 Chief Executive Officer 60 16-07-19
Weihao Xu DFI
 Director of Finance/CFO 42 21-11-30
Hong Amy Que CTO
 Chief Tech/Sci/R&D Officer 59 21-05-31
Members of the board TitleAgeSince
Albert Collinson BRD
 Director/Board Member 66 23-07-12
Robert Kamen BRD
 Director/Board Member 79 16-11-30
Wei Wei Chen BRD
 Director/Board Member 58 -
More insiders

ETFs positioned on HBM Holdings Limited

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.78% 4 M€ -27.92%
More ETFs positioned on HBM Holdings Limited

Quotes

Date Price Change Volume
24-04-28 1.29 +3.20% 1 156 000
24-04-26 1.25 +5.04% 1,592,000
24-04-25 1.19 +6.25% 1,961,000
24-04-24 1.12 -2.61% 1,303,000
24-04-23 1.15 +6.48% 2,107,280

Delayed Quote Hong Kong S.E., April 28, 2024 at 11:36 pm

More quotes

Company Profile

HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
Sector
Pharmaceuticals
Calendar
2024-08-26 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
HBM HOLDINGS LIMITED Stock HBM Holdings Limited
-33.51% 117M
CSL LIMITED Stock CSL Limited
-4.65% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 2142 Stock